Protein and transcript expression levels of TRIP13 signify worse prognosis in endometrioid carcinoma

Abstract

Abstract This study investigated the genes implicated in endometrioid adenocarcinoma development to provide insights into the molecular diagnosis, targeted therapy, and prognostic prediction of the disease. Two mRNA microarray datasets were obtained from the Gene Expression Omnibus. Differentially expressed genes were identified, and a protein–protein interaction network was constructed. Gene Ontology and Kyoto Encyclopedia of Genes and Genomes enrichment analyses were performed on the genes within the network modules. Prognostic significance was determined through a survival analysis to identify the key genes. The UALCAN website was used to validate TRIP13 mRNA expression, and immunohistochemical staining was performed to evaluate TRIP13 protein expression in patient samples. Sixteen genes were significantly associated with patient prognosis. The results revealed significantly elevated TRIP13 transcription and protein expression levels in endometrial cancer tissues compared to those in normal tissues. High TRIP13 expression was significantly correlated with shorter survival and considered an independent risk factor for endometrioid adenocarcinoma. Further, a negative correlation between TRIP13 expression and infiltrating CD8 + T cell levels in uterine corpus endometrial carcinoma was observed. This study validated the correlation between TRIP13 expression and poor patient prognosis, suggesting that TRIP13 may be a biomarker for endometrioid adenocarcinoma prognosis predictions.